Source comparison
Tesamorelin Dosage for HIV Lipodystrophy: Protocol Comparison
1mg SC daily 8.2% (95% CI: 6.1–10.3%) 22% discontinuation due to AEs Subtherapeutic. Not recommended 2mg SC daily (bedtime) 15.6% (95% CI: 13.2–18.0%) 28% discontinuation due to AEs FDA-approved standard. Proven efficacy 3mg SC daily 16.1% (95% CI: 13.5–18.7%)
This comparison does not assign a generated winner or score.
- 1mg SC daily
- 8.2% (95% CI: 6.1–10.3%)
- 22% discontinuation due to AEs
- Subtherapeutic. Not recommended
- 2mg SC daily (bedtime)
- 15.6% (95% CI: 13.2–18.0%)
- 28% discontinuation due to AEs
- FDA-approved standard. Proven efficacy
- 3mg SC daily
- 16.1% (95% CI: 13.5–18.7%)
- 41% discontinuation due to AEs
- No added benefit. Higher AE burden
- 2mg SC (morning dosing)
- 11.3% (observational)
- 32% discontinuation due to AEs
- Misaligned with circadian GH rhythm. Inferior outcomes